Protara Therapeutics, Inc. (TARA) Discusses Interim Results From Phase II STARBORN-1 Trial of TARA-002 in Pediatric Lymphatic Malformations November 19, 2025 8:30 AM EST
Company Participants
Justine O’Malley – Senior Vice President of Investor Relations & Corporate Affairs
Jesse Shefferman – Co-founder, CEO, President & Director
Jacqueline Zummo – Co-Founder & Chief Scientific Operations Officer
William Conkling – Chief Commercial Officer
Conference Call Participants
Jesse Jones
Li Wang Watsek – Cantor Fitzgerald & Co., Research Division
Soumit Roy – JonesTrading Institutional Services, LLC, Research Division
Vishwesh Shah – TD Cowen, Research Division
Yue-Wen Zhu – LifeSci Capital, LLC, Research Division
Leland Gershell – Oppenheimer & Co. Inc., Research Division
Presentation
Operator
Hello, and welcome to the Protara Update Call. We ask that you please hold all questions until the completion of the formal remarks at which time you will be given instructions for the question-and-answer session. Also, as a reminder, this conference is being recorded. If you have any objections, please disconnect at this time.
With that, I would now like to turn the call over to Justine O’Malley, Senior Vice President, Investor Relations and Corporate Affairs.
Justine O’Malley
Senior Vice President of Investor Relations & Corporate Affairs
Thank you very much. Good morning. Thank you all for joining us today for a review of the interim results of our ongoing Phase II open-label STARBORN-1 trial of TARA-002 in pediatric patients with macrocystic and mixed cystic lymphatic malformations or LMs.
Before we begin, I would like to remind you that during today’s call, we will be making certain forward-looking statements. These statements represent our views as of today only and should not be relied upon as representing our views as of any subsequent date. Actual results may differ from our forward-looking statements due to various factors, including those described in the Risk Factors section of our most recent annual report and
